Quantcast

Latest Percutaneous tibial nerve stimulation Stories

2014-08-11 16:28:13

MINNEAPOLIS, Aug. 11, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that National Government Services (NGS) has issued a positive coverage decision for Posterior Tibial Nerve Stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence associated with overactive bladder (OAB). Coverage for...

2014-08-06 08:30:46

MINNEAPOLIS, Aug. 6, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13. Rob Kill, President and CEO, will present at 5:00pm ET and meet with investors one on one at the conference at the Intercontinental Hotel Boston....

2014-07-10 08:27:22

MINNEAPOLIS, July 10, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, will release financial results for the first quarter ended June 30, 2014 after the market close on Thursday, July 24, 2014. The Company will host a conference call and webcast to discuss these results on Thursday, July 24, 2014 at 4:30 p.m. Eastern Time (3:30 p.m. Central...

2014-06-30 08:29:46

MINNEAPOLIS, June 30, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, reported that in the recently updated Overactive Bladder (OAB) treatment guideline from the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), Percutaneous Tibial Nerve Stimulation (PTNS) is...

2014-06-16 08:27:52

MINNEAPOLIS, June 16, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24. Rob Kill, President and CEO, will present at 1:00pm ET and meet with investors one on one at the conference at The Westin New York Grand Central. Attendance...

2014-06-02 08:29:20

~Roche Brings Deep Healthcare Industry and Business Strategy Experience MINNEAPOLIS, June 2, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Kevin H. Roche has been appointed to the Company's Board of Directors effective May 29, 2014. Mr. Roche will chair the Nominating Committee and also serve as a member of Uroplasty's...

2014-05-01 08:35:10

MINNEAPOLIS, May 1, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the fourth quarter and fiscal year 2014 ended March 31, 2014 at the market close on Thursday, May 15, 2014. The Company will host a conference call and webcast to discuss these results on Thursday, May 15, 2014 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). Rob Kill, President and Chief Executive Officer, and Brett Reynolds, Chief Financial Officer,...

2014-04-17 08:27:52

MINNEAPOLIS, April 17, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Daniel P. Merz has joined the Company as Vice President of Healthcare Affairs. In this role, he will oversee Uroplasty's strategy to educate payors and providers of the efficiency, effectiveness and overall value of the Company's products. He joins...

2014-02-26 08:28:02

MINNEAPOLIS, Feb. 26, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 26th Annual ROTH Conference on Tuesday, March 11, 2014. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 8:30am PT and meet with investors one on one at the conference at the Ritz...

2014-02-06 08:27:59

~Positive Coverage Decision Adds 2.2 Million Covered Lives for Up to Two Years of Treatment with Urgent PC MINNEAPOLIS, Feb. 6, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Independence Blue Cross (IBC) has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related